|Clinical UM Guideline|
|Subject: Corneal Collagen Cross-Linking|
|Guideline #: CG-SURG-105||Publish Date: 12/16/2020|
|Status: Reviewed||Last Review Date: 11/05/2020|
This document addresses corneal collagen cross-linking (CXL, also known as 3-CR or C3R), a minimally invasive photochemical treatment of progressive keratoconus and other corneal thinning processes, such as ectasia after laser in-situ keratomileusis (LASIK).
Note: Please see the following related documents for additional information:
Corneal collagen cross-linking (CXL) is considered medically necessary as a treatment for progressive keratoconus when all of the following conditions are met:
Corneal collagen cross-linking (CXL) is considered medically necessary as a treatment for corneal ectasia resulting from refractive surgery (e.g. LASIK) when all of the following conditions are met:
Not Medically Necessary:
Corneal collagen cross-linking (CXL) is considered not medically necessary when the above criteria have not been met and for all other indications.
The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
When services may be Medically Necessary when criteria are met:
Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)
Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL [Photrexa, Photrexa Viscous]
When services are Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met or for all other diagnoses not listed.
According to the National Eye Institute, keratoconus is the most common corneal dystrophy in the United States and reportedly affects approximately 1 in every 2000 Americans (2011). This progressive bilateral eye dystrophy is more prevalent in teens and young adults and is characterized by central steepening and stromal thinning of the cornea that impair visual acuity.
Initial treatment often consists of hard contact lenses. A penetrating keratoplasty (i.e., corneal graft) is the next line of treatment for those individuals who develop intolerance to contact lenses. While visual acuity is typically improved with a keratoplasty, there is an associated risk of perioperative complications, long-term topical steroid use is required and endothelial cell loss occurs over time, which is a particular concern in younger individuals.
As an alternative, a variety of keratorefractive procedures have been attempted. Subtractive techniques include LASIK, but in general, results of this technique have been poor. Implantation of intrastromal corneal ring segments represents an additive technique where the implants are intended to reinforce the cornea, prevent further deterioration and potentially obviate the need for a penetrating keratoplasty.
Corneal CXL is another potential alternative to immediate keratoplasty. This procedure is performed in the outpatient setting using topical anesthesia with the photosensitizer riboflavin (vitamin B2) and ultraviolet-A (UVA) irradiation. It involves removing approximately 8 mm of the central corneal epithelium to allow better diffusion of the photosensitizer into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with 370 nm UVA. The interaction of riboflavin and UVA causes the formation of covalent bonds between collagen molecules. Preclinical studies demonstrated increased corneal rigidity and stability following CXL. CXL could potentially slow the progression of keratoconus.
Corneal CXL is also a potential treatment for post-LASIK ectasia. Ectasia also known as iatrogenic keratoconus or secondary keratoconus is a serious long-term complication of LASIK surgery. Reported treatments for the management of post-LASIK ectasia include hard contact lenses, intraocular pressure-lowering drugs, and intracorneal ring segments. Frequently, a penetrating keratoplasty is required.
Several systematic reviews and meta-analyses of the published literature on corneal CXL for treating keratoconus have been published (Kobashi. 2017; Li, 2016; Meiri, 2016; Sykakis, 2015). Most recently, Kobashi and Rong (2017) conducted a review of randomized controlled trials (RCTs) evaluating corneal CXL for progressive keratoconus that had at least 1 year of follow-up. Studies on individuals with a history of corneal surgery and on combination treatment were excluded. Five trials with a total of 289 eyes met the review’s inclusion criteria. The number of treated eyes in the RCTs ranged from 15 to 29. Three of the studies used the contralateral eye in the same individual as the control and the other two studies used different individuals matched for age and progression of keratoconus.
A meta-analysis of data from four of the studies on best corrected visual acuity (BCVA) found a statistically significant increase in the corneal CXL group compared with the control group at 12 months (weighted mean difference [WMD], -0.09, 95% confidence interval [CI], -0.14 to -0.04; p<0.001). The authors noted that the difference between groups was not likely to be clinically significant because it was less than one line on an eye chart and is within the range of typical test-retest variability. A meta-analysis of data from three studies on change in thinnest corneal thickness did not differ significantly between groups at 12 months (WMD, 1.46; 95% CI, -2.77 to 5.68). Other outcomes were not pooled due to high heterogeneity. Maximum keratometry (Kmax) was reported in all studies. In three studies, the Kmax was significantly reduced in the corneal CXL group compared with control and in the other two studies, the difference between groups was not statistically significant at the p<0.05 level. The authors concluded that CXL may be able to halt the progression of keratoconus for 1 year, but the evidence base is limited by the paucity of RCTs and significant heterogeneity among studies.
A 2015 Cochrane review included three randomized controlled trials (RCTs) that analyzed 219 eyes; 100 served as controls. The overall quality of the RCTs was deemed poor by the authors; all of the studies were hampered by a high risk for performance bias, detection bias and attrition bias. Outcome measures reported across the studies differed to the extent that pooling of data was not possible and no data was reported on quality of life outcomes. The authors concluded that, “The evidence for the use of CXL in the management of keratoconus is limited due to the lack of properly conducted RCTs.”
RCT data submitted as part of FDA approval on individuals with progressive keratoconus were published initially in 2011 and then in 2017 by Hersh and colleagues. The eligibility criteria for the RCT included age 14 or older, topography patterns consistent with keratoconus and no previous corneal surgery. A total of 205 eyes were treated with CXL (n=102) or sham treatment with riboflavin plus dextran solution alone (n=103). Participants in the sham control group were able to cross over to the treatment group after 3 months. At 12 months, only 2 eyes (2%) remained in the control group; therefore the analysis used a last observation carried forward (LOCF) method. The number of actual control eyes was 96 (93%) at 3 months and 39 (38%) at 6 months.
The primary outcome in the Hersh study was mean change in maximum keratometry (K) from baseline to month 12. Using the LOCF method, maximum K decreased a mean of 1.6 D in the CXL group and increased a mean of 1.0 D in the control group. The difference between groups was statistically significant, p<0.0001. The between-group difference exceeded the 1.0 D difference that was pre-specified as being clinically meaningful. Using the LOCF method, the mean difference in corrected distance visual acuity (CDVA) was a 5.7 letter improvement in the treatment group and a 2.2 letter improvement in the control group. The between-group difference in CDVA was statistically significant, p<0.001.
There were a number of ocular adverse events that occurred in at least 10% of individuals in the CXL group. The most frequent of these were corneal opacity (57%), punctate keratitis (25%), corneal striae (24%) and epithelial defect after 1 week (23%). In the control group, the only adverse event affecting more than 10% of participants was corneal striae (12%). A limitation of the study is that it had a cross-over design at 3 months and thus comparative data beyond 3 months are unreliable.
Two smaller RCTs have also been published. In 2014, Wittig-Silva and colleagues reported results from an open-label trial evaluating the efficacy and safety of CXL using 0.1% riboflavin and UVA in the management of progressive keratoconus. A total of 100 eyes were randomized to either a treatment (n=50) or control (n=50) group. (The authors only reported on number of eyes, not number of participants). The control group received usual care and was offered “compassionate CXL treatment” no earlier than 6 months after randomization. A total of 12 eyes received compassionate CXL and were excluded from further analysis. The final analysis at 36 months included 41 treatment eyes and 27 control eyes, 68% of the randomized study population.
The primary outcome of maximum simulated keratometry value (Kmax) increased by a mean of 1.20 ± 0.28 diopters, 1.70 ± 0.36 diopters, and 1.75 ± 0.38 diopters at 12, 24, and 36 months, respectively (all p<0.001) in the control group. Whereas, in treated eyes, Kmax decreased by -0.72 ± 0.15 diopters, -0.96 ± 0.16 diopters, and -1.03 ± 0.19 diopters at 12, 24, and 36 months, respectively (all between-group comparisons p<0.001). The mean change in uncorrected visual acuity (UCVA) showed deterioration in the control group (+0.10 ± 0.04 logMAR; p=0.034) at 36 months, whereas in the treatment group, both UCVA (-0.15 ± 0.06 logMAR; p=0.009) and best spectacle-corrected visual acuity (BSCVA) (-0.09 ± 0.03 logMAR; p=0.006) improved at 36 months. A total of 2 eyes had minor complications that did not affect the final visual acuity. The study showed a positive effect of CXL compared with usual care but was limited by the relatively small sample size, substantial dropout rate at 36 months and lack of blinding or sham-control.
A randomized sham and fellow-eye controlled prospective trial by Greenstein and colleagues (2011) involving 82 eyes, found that after CXL the cornea thins but then recovers toward baseline thickness by 6 months. The cause and clinical implications of corneal thickness changes with CXL require further study.
Additionally, a number of uncontrolled studies have been published on the use of CXL for keratoconus. Studies were conducted with adult populations (Asri 2011; Chatzis, 2012; Coskunseven, 2009; De Bernardo, 2014; Derakhshan, 2011; Grewal 2009; Hashemi, 2013; Raiskup-Wolf, 2015; Vinciguerra, 2012) and pediatric populations (Caporossi, 2012; Caporossi, 2010; Knutsson, 2018; Mazzotta, 2018).
Several of the case series provided long-term follow-up data. Raiskup-Wolf and colleagues (2015) published 10-year follow-up data from a retrospective case series that enrolled 24 individuals (34 eyes) with progressive keratoconus who were treated with corneal CXL. Maximum K was lower after 10 years than at baseline (p<0.001). Mean CDVA improved by 0.14 logMAR at follow-up, which was significantly better than at baseline. Two individuals had repeat CXL due to symptom progression.
In 2018, Mazzotta and colleagues reported 10-year follow-up of a study of CXL in pediatric subjects age 18 years and younger. The study cohort originally consisted of 152 eyes, and 62 eyes (40%) in 47 individuals who were available for follow-up at 10 years. The mean age at baseline of the evaluable individuals was 14 years (range: 8 to 18 years). Mean CVDA and mean uncorrected distance visual acuity (UVDA) improved at all follow-up visits compared with baseline. The improvement was significantly better than baseline each year through year 10 (p=0.001). Maximum K improved significantly starting 6 months after treatment (p=0.0454) and continuing through the eighth year of follow-up. The 10-year keratoconus progression rate was 26% of participants and 24% of eyes.
A 2017 RCT by Hersh and colleagues focused on corneal CXL for treating corneal ectasia after laser refractive surgery. The study pooled data on individuals with corneal ectasia from two pivotal trials. In both trials, the eligibility criteria included age 14 or older, topography patterns consistent with corneal ectasia and no previous corneal surgery other than corneal refractive surgery. A total of 179 eyes were randomized to treatment with CXL (n=91) or sham treatment with riboflavin alone (n=88). Participants in the sham control group were able to cross over to the treatment group after 3 months. At 12 months, only 2 eyes (2%) remained in the control group; therefore the analysis used a last observation carried forward (LOCF) method. The number of actual control eyes was 85 (97%) at 3 months and 32 (36%) at 6 months.
The primary outcome was mean change in maximum K from baseline to month 12. Using the LOCF method, at 12 months maximum K decreased a mean of 1.3 D in the CXL group and increased a mean of 0.8 D in the control group, a statistically significant difference, p<0.0001. The between-group difference exceeded the 1.0 D difference that was pre-specified as being clinically meaningful. Using the LOCF method, the difference in corrected distance visual acuity (CDVA) was a 5 letter improvement in the treatment group and a 0.3 letter decrease in the control group. The between-group difference in CDVA was statistically significant, p<0.001. There were a number of ocular adverse events that occurred in at least 5% of individuals in the CXL group. The most frequent of these were corneal opacity (68%), epithelial defect after 1 week (26%) and eye pain (26%), punctate keratitis (20%) and photophobia (19%). A limitation of the study is that it had a cross-over design at 3 months and thus comparative data beyond 3 months are unreliable. There is a lack of comparative data on long-term outcomes after corneal CXL for corneal ectasia.
In April 2016, the US Food and Drug Administration (FDA) granted approval for Photrexa® (riboflavin 5’-phosphate ophthalmic solution) 0.146% and Photrexa Viscous® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) 0.146% to be used along with the KXL® collagen cross-linking system (Avedro Inc.; Waltham, MA) for treatment of progressive keratoconus and corneal ectasia following refractive surgery. According to the Product Information (PI) Label (2016), approval of Avedros’ CXL system was based on three open-label Phase III clinical trials conducted in the United States (n=364). Maximum K was the primary outcome.
Other Potential Indications
A 2020 Cochrane review (Davis, 2020) evaluated published literature on photoactivated chromophore for collagen cross-linking (PACK-CXL) for bacterial infectious keratitis. The authors identified two RCTs and one quasi-RCT, with a total of 59 participants, comparing PACK-CXL to standard therapy such as medication treatment. All of the studies were conducted outside of the U.S. The authors did not pool study findings because primary outcomes differed in each of the studies. They judged the certainty of the evidence to be very low because of the small sample sizes in individual studies as well as the small number of total participants, and heterogeneity of the study populations and outcomes.
The evidence base on corneal CXL for progressive keratoconus and corneal ectasia continues to have limitations, especially the paucity of long-term comparative data on safety and efficacy. However, the pivotal trials have positive 12-month findings using imputed data, and the smaller open-label Wittig-Silva trial found better outcomes at 3 years in the corneal crosslink group compared with standard care. Moreover, case series have found a durable impact of corneal CXL on health outcomes in both adults and children at up to 10 years. In addition, there is growing consensus in the ophthalmology practice community that corneal CXL provides significant benefits over standard care in terms of improving health outcomes, reducing the rate of keratoplasties. The evidence base to support any other indications for corneal CXL remains limited.
Astigmatism: The astigmatism is the difference in any two meridians of the cornea and the crystalline lens in the eye. Typically, it is measured the two meridians that are 90 degrees apart from one another. The astigmatism in your glasses neutralizes the astigmatism in the eye. Normally, most of the astigmatism is in the cornea.
Cornea: The outermost layer of the eye; dome shaped and covers the front of the eye.
Ectasia: A condition that occurs when the cornea is so thin that pressure within the eye leads to bulging of the cornea.
Keratoconus: Cone-shaped cornea with the apex of the cone being forward; also called conical cornea.
Keratometry (K): Masurement of the curvature of the cornea.
Manifest cylinder: A subjective measure of a change in the cylinder (astigmatism). For example, an increase of 1.00 D or more in manifest cylinder indicates that the glasses prescription astigmatism has changed by 1 or more.
Manifest refraction spherical equivalent (MRSE): A subjective measure of a change in the cylinder (astigmatism). It is calculated arithmetically by adding the sphere power and half of the cylinder power. MRSE is used in the calculation of spherical equivalent.
Peer Reviewed Publications:
Government Agency, Medical Society, and Other Authoritative Publications:
|Websites for Additional Information|
Corneal cross-linking (CXL)
The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.
Medical Policy & Technology Assessment Committee (MPTAC) review. Discussion/General Information and References sections updated. Reformatted Coding section.
MPTAC review. Initial document development. Moved content of MED.00109 to new clinical utilization management guideline document with the same title. Edited criterion B in medically necessary statement on progressive keratoconus for clarification.
Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.
Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.
No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.
© CPT Only - American Medical Association